# Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

> **NCT00400634** · PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 58 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
- **PROCEDURE:** Sham Surgery

## Key facts

- **NCT ID:** NCT00400634
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400634, "Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00400634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*